Cannabinoid receptor ligands
2 Assignments
0 Petitions
Accused Products
Abstract
There are disclosed compounds of the formula
a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds and methods of using the compounds for the treatment of various diseases and conditions.
-
Citations
57 Claims
-
1. A compound of the formula
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)
-
2. A compound according to claim 1 wherein p1 L1 is —
- SO2—
, —
CH2—
, —
CHCH3—
,
- SO2—
-
3. The compound according to claim 2 wherein
L1 is — - SO2—
or —
CH2—
;
L is —
SO2—
;
R1 is CH3or CF3;
andR4 is phenyl, pyrimidyl or pyridyl, each of said phenyl, pyrimidyl or pyridyl optionally substituted with one to three substitutents which are the same or different, and are independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, OH, CF3 and halogen.
- SO2—
-
4. The compound according to claim 3 wherein the phenyl in R4 is substituted with OCH3 or halogen.
-
5. The compound according to claim 4 wherein the halogen is selected from fluorine and chlorine.
-
6. The compound according to claim 1 of the formula
-
7. The compound according to claim 1 of the formula
-
8. The compound according to claim 1 of the formula
-
9. The compound according to claim 1 of the formula
-
10. The compound according to claim 1 of the formula
-
11. The compound according to claim 1 of the formula
-
12. The compound according to claim 1 of the formula
-
13. The compound according to claim 1 of the formula
-
14. The compound according to claim 1 of the formula
-
15. The compound according to claim 1 of the formula
-
16. The compound according to claim 1 of the formula
-
17. The compound according to claim 1 of the formula
-
18. The compound according to claim 1 of the formula
-
19. The compound according to claim 1 of the formula
-
20. The compound according to claim 1 of the formula
-
21. The compound according to claim 1 of the formula
-
22. The compound according to claim 1 of the formula
-
23. The compound according to claim 1 of the formula
-
24. The compound according to claim 1 of the formula
-
25. The compound according to claim 1 of the formula
-
26. The compound according to claim 1 of the formula
-
27. The compound according to claim 1 of the formula
-
28. The compound according to claim 1 of the formula
-
29. The compound according to claim 1 of the formula
-
30. A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 1 and a pharmaceutically acceptable carrier.
-
31. A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 7 and a pharmaceutically acceptable carrier.
-
32. A method of stimulating cannabinoid CB2 receptors in a mammal comprising administering to a mammal having CB2 receptors an effective CB2 receptor stimulating amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 1.
-
33. A method of treating cancer, inflammatory diseases, immunomodulatory diseases, or respiratory diseases comprising administering to a mammal in need of such treatment an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 1.
-
34. A method of treating cutaneous T cell lymphoma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, glaucoma, diabetes, sepsis, shock, sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, retinal disease, scleroderma, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing alveolitis, psoriasis, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, Crohn'"'"'s disease, inflammatory bowel disease, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, colitis, coronary artery disease, melanoma, transplant rejection, graft versus host disease, Hashimoto'"'"'s thyroiditis, Graves disease, myasthenia gravis or Goodpasture'"'"'s syndrome comprising administering to a mammal in need of such treatment an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 1.
-
35. The method of claim 32 wherein the condition or disease treated is selected from rheumatoid arthritis, multiple sclerosis, seasonal allergic rhinitis and chronic obstructive pulmonary disease.
-
36. A pharmaceutical composition made by combining the compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, of claim 1 and a pharmaceutically acceptable carrier therefor.
-
37. A process for making a pharmaceutical composition comprising combining a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, of claim 1 and a pharmaceutically acceptable carrier.
-
38. A method of treating rheumatoid arthritis which comprises co-administration of a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF-α
- compound or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 1.
-
39. A method of treating rheumatoid arthritis which comprises co-administration of a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF-α
- compound, a PDE IV inhibitor or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 7.
-
40. The method of claim 38 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β
- -methasone and the anti-TNF-α
compound is Enbrel or Remicade.
- -methasone and the anti-TNF-α
-
41. The method of claim 39 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β
- -methasone and the anti-TNF-α
compound is Enbrel or Remicade.
- -methasone and the anti-TNF-α
-
42. A composition for treating rheumatoid arthritis which comprises a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF-α
- compound or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 1.
-
43. A composition for treating rheumatoid arthritis which comprises a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF-α
- compound or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 7.
-
44. The composition of claim 42 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β
- -methasone and the anti-TNF-α
compound is Enbrel or Remicade.
- -methasone and the anti-TNF-α
-
45. The composition of claim 43 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β
- -methasone and the anti-TNF-α
compound is Enbrel or Remicade.
- -methasone and the anti-TNF-α
-
46. A method of treating multiple sclerosis which comprises co-administration of a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 1.
-
47. A method of treating multiple sclerosis which comprises co-administration of a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 7.
-
48. A composition for treating multiple sclerosis which comprises a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 1.
-
49. A composition for treating multiple sclerosis which comprises a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 7.
-
50. A method of treating psoriasis which comprises co-administration of a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF-α
- compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 1.
-
51. A method of treating psoriasis which comprises co-administration of a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF-α
- compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 7.
-
52. The method of claim 50 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β
- -methasone and the anti-TNF-α
compound is Enbrel or Remicade.
- -methasone and the anti-TNF-α
-
53. The method of claim 51 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β
- -methasone and the anti-TNF-α
compound is Enbrel or Remicade.
- -methasone and the anti-TNF-α
-
54. A composition for treating psoriasis which comprises a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF-α
- compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 1.
-
55. A composition for treating psoriasis which comprises a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF-α
- compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in claim 7.
-
56. The composition of claim 54 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β
- -methasone and the anti-TNF-α
compound is Enbrel or Remicade.
- -methasone and the anti-TNF-α
-
57. The composition of claim 55 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β
- -methasone and the anti-TNF-α
compound is Enbrel or Remicade.
- -methasone and the anti-TNF-α
-
2. A compound according to claim 1 wherein p1 L1 is —
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeMerck Sharp & Dohme Corporation (Merck & Co., Inc.)
-
Original AssigneeSchering Corporation (Merck & Co., Inc.)
-
InventorsShih, Neng-Yang, Lavey, Brian J., Tong, Ling, Shankar, Bandarpalle B., Kozlowski, Joseph A., Wolin, Ronald L., Wong, Michael K., Rizvi, Razia K., Spitler, James M.
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/332
-
CPC Class CodesA61P 1/04 for ulcers, gastritis or re...A61P 1/16 for liver or gallbladder di...A61P 11/00 Drugs for disorders of the ...A61P 11/02 Nasal agents, e.g. deconges...A61P 11/06 AntiasthmaticsA61P 11/08 BronchodilatorsA61P 11/16 Central respiratory analepticsA61P 13/12 of the kidneysA61P 17/00 Drugs for dermatological di...A61P 17/02 for treating wounds, ulcers...A61P 17/06 AntipsoriaticsA61P 19/02 for joint disorders, e.g. a...A61P 19/10 for osteoporosisA61P 21/04 for myasthenia gravisA61P 25/00 Drugs for disorders of the ...A61P 27/02 Ophthalmic agentsA61P 27/06 Antiglaucoma agents or mioticsA61P 29/00 Non-central analgesic, anti...A61P 3/10 for hyperglycaemia, e.g. an...A61P 31/04 Antibacterial agentsA61P 35/00 : Antineoplastic agentsA61P 35/02 : specific for leukemiaA61P 37/00 : Drugs for immunological or ...A61P 37/02 : ImmunomodulatorsA61P 37/06 : Immunosuppressants, e.g. dr...A61P 37/08 : Antiallergic agents antiast...A61P 43/00 : Drugs for specific purposes...A61P 9/00 : Drugs for disorders of the ...A61P 9/10 : for treating ischaemic or a...A61P 9/14 : Vasoprotectives; Antihaemor...C07C 2601/02 : with a three-membered ringC07C 2601/08 : the ring being saturatedC07C 2601/14 : The ring being saturatedC07C 2603/74 : AdamantanesC07C 31/24 : Tetrahydroxylic alcohols, e...C07C 317/22 : with sulfone or sulfoxide g...C07C 317/32 : with sulfone or sulfoxide g...C07C 317/36 : with the nitrogen atoms of ...C07C 317/44 : having sulfone or sulfoxide...C07C 323/41 : Y being a hydrogen or an ac...C07C 323/65 : containing sulfur atoms of ...C07D 213/70 : Sulfur atomsC07D 213/71 : to which a second hetero at...C07D 213/74 : Amino or imino radicals sub...C07D 213/89 : with hetero atoms directly ...C07D 215/36 : Sulfur atoms C07D215/24 tak...C07D 233/42 : Sulfur atomsC07D 233/84 : Sulfur atomsC07D 239/38 : One sulfur atomC07D 307/64 : Sulfur atomsC07D 333/20 : by nitrogen atoms nitro, ni...C07D 333/34 : Sulfur atomsC07D 333/38 : Carbon atoms having three b...